股票代码：002433 股票简称：*ST 太安 公告编号：2023-084 广东太安堂药业股份有限公司 关于控股股东部分股份被轮候冻结和股东部分股份被司 法再冻结的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、本次股东股份被司法再冻结、轮候冻结的情况 特别风险提示： 控股股东累计被冻结股份数量（含本次）占其所持公司股份数量比例超过 80%，请投资者注意相关风险。 广东太安堂药业股份有限公司（以下简称"公司"）于近日通过中国证券登 记结算有限责任公司系统查询，获悉公司控股股东太安堂集团有限公司（以下简 称"太安堂集团"）所持有公司的部分股份被轮候冻结、公司股东柯少芳女士所 持有公司的部分股份被司法再冻结，现将具体情况公告如下： （一）股东股份被司法再冻结的情况 | | 是否为控股 | | 占其所 | 占公司 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 | 股东或第一 | 本次被冻结股 | 持股份 | 总股本 | 起始 | 到期 | 冻结申 | 原因 ...

股票代码：002433 股票简称：*ST 太安 公告编号：2023-085 广东太安堂药业股份有限公司 股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 广东太安堂药业股份有限公司（以下简称"公司"）股票交易价格连续3个 交易日（2023年9月12日、9月13日、9月14日）日收盘价格涨跌幅偏离值累计偏 离13.19%，根据深圳证券交易所的相关规定，属于股票交易异常波动的情况。 二、公司关注并核实的相关情况 针对公司股票交易异常波动，公司董事会对公司、控股股东就有关事项进行 核查，现将有关情况说明如下： 1、公司前期披露的信息截止本公告提交披露时不存在需要补充、更正之处。 2、公司未发现近期公共媒体报道了可能或已经对本公司股票交易价格产生 较大影响的未公开重大信息。 3、因公司2022年度经审计的归属于上市公司股东的净利润为-82,282.23万 元，公司2022年度财务会计报告被出具无法表示意见，公司股票自2023年5月5 日起被实施"退市风险警示"。此外，公司还因触及最近三个会计年度扣除非经 常性损益前 ...

北 京 上 海 深 圳 杭 州 广 州 昆 明 天 津 成 都 宁 波 福 州 西 安 南 京 南 宁 济 南 重 庆 苏 州 长 沙 太 原 武 汉 贵 阳 乌鲁木齐 郑 州 石家庄 合 肥 海 南 青 岛 南 昌 大 连 银 川 拉 孜 香 港 巴 黎 马德里 硅 谷 斯德哥尔摩 纽 约 广州市天河区珠江东路 28 号越秀金融大厦 38 楼 邮编：510623 电话：(+86)(20) 3879 9345 传真：(+86)(20) 3879 9345-200 国浩律师(广州)事务所 关于广东太安堂药业股份有限公司 2023 年第四次临时股东大会的法律意见 广东太安堂药业股份有限公司： 根据中国证券监督管理委员会发布的《上市公司股东大会规则》(以下简称 《股东大会规则》)的要求，国浩律师(广州)事务所(以下简称"本所")接受广 东太安堂药业股份有限公司(以下简称"太安堂")的委托，指派郭佳、杨雪莹律 师(以下简称"本所律师")出席太安堂 2023 年第四次临时股东大会(以下简称 "本次股东大会")，对本次股东大会的召集与召开程序、出席会议人员与召集 人的资格、表决程序与表决结果等重要事项出具法律意见。由于台 ...

股票代码：002433 股票简称：*ST 太安 公告编号：2023-083 广东太安堂药业股份有限公司 2023年第四次临时股东大会决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无否决提案的情形。 2、本次股东大会不涉及变更前次股东大会决议。 一、会议召开情况 1、会议召开时间 现场会议时间：2023年9月4日（星期四）下午2:50 网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为2023 年9月4日上午9:15-9:25，9:30-11:30，下午13:00-15:00；通过深圳证券交易所 互联网投票系统投票的具体时间为：2023年9月4日9:15-15:00期间的任意时间。 2、现场会议召开地点：汕头市金园工业区揭阳路28号广东太安堂药业股份 有限公司（以下简称"公司"或"太安堂"）麒麟园中座二楼会议室 3、会议召开方式：现场投票和网络投票相结合方式 参加本次股东大会的股东（或股东代理人）共 269 人，代表公司表决权的股 份数 195,126,459 股，占公司表决权股份总数 766,773,200 股 ...

股票代码：002433 股票简称：*ST 太安 公告编号：2023-083 广东太安堂药业股份有限公司 关于控股股东及其关联方非经营性资金占用清欠进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、截至本公告披露日，控股股东非经营性资金占用尚未偿还的金额为 49,156.13万元。 2、如相关方无法全部清偿占用上市公司的资金，将影响公司的财务状况， 损害上市公司和中小股东的利益，请广大投资者注意投资风险。 一、公司控股股东及其关联方非经营性资金占用的情况 根据广东太安堂药业股份有限公司（以下简称"公司"）2022年半年度报告 披露，公司存在控股股东及其关联方非经营性占用公司资金的情形，控股股东太 安堂集团有限公司（以下简称"太安堂集团"）通过间接划转款项方式占用上市 公司资金25,125.30万元，后经确认为25,395.24万元。公司自2022年9月28日起 被实施其他风险警示。有关内容详见公司2022年9月27日披露的《关于公司股票 被实行其他风险警示的公告》（公告编号：2022-065）。 根据公司2022年年度报告披露，截至202 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥261,136,901.30, a decrease of 48.77% compared to the same period last year[25]. - The net loss attributable to shareholders was ¥106,097,464.44, showing an improvement of 6.39% from a loss of ¥113,336,156.13 in the previous year[25]. - The net cash flow from operating activities decreased by 51.42% to ¥25,753,551.05 compared to ¥53,015,804.87 in the same period last year[25]. - Total assets at the end of the reporting period were ¥6,321,753,757.69, down 3.67% from the previous year-end[25]. - The company reported a basic earnings per share of -¥0.14, an improvement of 6.67% from -¥0.15 in the previous year[25]. - The weighted average return on net assets was -2.98%, a decrease of 0.39% compared to -2.59% in the previous year[25]. - The company achieved total revenue of CNY 261,136,901.30, a decrease of 48.77% compared to the same period last year[48]. - The company reported an operating profit of CNY -117,706,062.42, an increase of 11.19% year-on-year[48]. - The net profit attributable to shareholders was CNY -106,097,464.44, reflecting a decrease of 6.39% compared to the previous year[48]. - The company reported a total of 13,391.83 million CNY in non-operating fund occupation by its controlling shareholder, with no repayments during the reporting period[103]. - The company reported a total liability of 35,464,828.00 CNY related to unpaid debts from the defendant, which constitutes a breach of contract[111]. - The company reported a total of 51,103 common shareholders at the end of the reporting period[143]. - The company reported a total of 49,156 million in assets during the reporting period[108]. Corporate Governance - The financial report includes a commitment from the management to ensure the accuracy and completeness of the financial statements[4]. - The report indicates that all board members attended the meeting to review the half-year report[4]. - The company has maintained a stable governance structure, ensuring the protection of shareholder rights and interests[95]. - The company has established a reasonable compensation and performance evaluation system to enhance employee motivation and creativity[95]. - The company has not faced any environmental penalties during the reporting period and adheres to environmental protection laws[94]. - The company has not engaged in any non-compliant external guarantees during the reporting period[106]. - The semi-annual financial report has not been audited[107]. - The board of directors acknowledged the non-standard audit report issued by Zhongxinghua Accounting Firm and will take effective measures to mitigate its adverse effects[108]. - The company has not reported any recent share buyback activities[140]. - The shareholder count and holding situation remain stable, with no significant changes reported[142]. Market Strategy and Operations - The company continues to focus on the development of traditional Chinese medicine products, which are a significant part of its portfolio[19]. - The management emphasizes the importance of adhering to Good Manufacturing Practice (GMP) and Good Supply Practice (GSP) standards in its operations[19]. - The company is focusing on integrating resources across the pharmaceutical and internet sectors to create a new healthcare ecosystem[42]. - The company plans to expand its market presence through improved sales management and the establishment of a comprehensive online and offline sales network[49]. - The company is actively involved in product research and development, including the secondary development of traditional Chinese medicine and new drug trials[50]. - The company is focusing on enhancing its core business by streamlining non-operational projects and investing in the production and sales of traditional Chinese medicine[47]. - The company aims to expand market share through marketing upgrades and standardized operations[85]. - The company plans to enhance market expansion strategies, focusing on new product development and technological advancements[175]. - The company is exploring potential mergers and acquisitions to strengthen its market position and expand its product portfolio[175]. - The company aims to improve operational efficiency through strategic cost management initiatives[178]. Financial Challenges and Risks - The company is facing risks related to policy changes, cost fluctuations in raw materials, and intensified market competition, which may impact profitability[82][83]. - The company is experiencing short-term debt repayment pressure due to reliance on bank loans for funding operations, including raw material procurement and market promotion[84]. - The company has not disclosed any significant changes in its registered address or contact information during the reporting period[22]. - The company has not made any acquisitions or significant market expansions as per the current report[19]. - The company has not engaged in any securities or derivative investments during the reporting period[76][77]. - The company has ongoing litigation involving a total amount of 3,392 million, which has been recognized as a liability[110]. - The company is actively communicating with creditors to resolve cash flow issues faced by its controlling shareholder due to macroeconomic conditions and industry policy adjustments[112]. Research and Development - The company has implemented strict quality control measures in line with the new GMP standards to enhance production efficiency and reduce costs[51]. - The company has allocated 3.6 million yuan for research and development in new technologies this year, aiming to improve product offerings[176]. - Research and development investment decreased by 38.44% to ¥4,068,744.47 from ¥6,609,727.33, attributed to insufficient funds[67]. - The company emphasizes the importance of new drug research and development, facing high investment, long cycles, and significant risks[84]. - Research and development expenses decreased to CNY 4,068,744.47 from CNY 6,609,727.33, indicating a reduction in R&D investment[164]. Social Responsibility and Compliance - The company is committed to corporate social responsibility, including employee rights protection and community engagement initiatives[52]. - The company has increased its tax contributions to the state and local governments, becoming a major taxpayer in its region[98]. - The company has a long-term commitment to environmental protection as part of its sustainable development strategy[97]. - The company has established an environmental management system to ensure compliance with pollution control measures[97]. - The company has not violated any environmental laws in the past three years, demonstrating compliance with environmental regulations and sustainable practices[98]. Shareholder Transactions - The controlling shareholder, Tai'an Tang Group, transferred 8,000,000 shares (1.04% of total shares) to Lin Baoyun to repay stock pledge financing debts and reduce pledge risks[138]. - A public auction was held for 11,700,000 shares held by Tai'an Tang Group, with the highest bidder winning the shares[139]. - The transfer of 8,000,000 shares was completed on April 27, 2023, and confirmed by the China Securities Depository and Clearing Corporation[139]. - The auctioned shares (11,700,000) were successfully transferred on July 19, 2023, following the auction[140]. - The total number of shares after the transfer remains at 766,773,000, maintaining 100% ownership structure[138]. - The company aims to stabilize control by reducing pledge risks through these share transactions[138]. Future Outlook - Future guidance indicates an expected revenue growth of 5% for the second half of 2023, driven by new product launches and market penetration efforts[176]. - The company plans to continue urging its controlling shareholders to take effective measures to raise funds promptly[108]. - The company intends to continue disposing of non-core heavy asset businesses to reinvest in its main traditional Chinese medicine manufacturing business[192].

广东太安堂药业股份有限公司独立董事 （下页无正文，为公司独立董事关于控股股东及其他关联方占用公司资金、公司 对外担保情况的专项说明和独立意见的签字页） （本页无正文，为公司独立董事关于控股股东及其他关联方占用公司资金、公司 对外担保情况的专项说明和独立意见的签字页） 独立董事签字： 关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项 说明和独立意见 根据《中华人民共和国公司法》、中国证券监督管理委员会《上市公司独 立董事管理办法》、《上市公司监管指引第 8 号——上市公司资金往来、对外担 保的监管要求》、深圳证券交易所《上市公司自律监管指引第 1 号——主板上市 公司规范运作》等法律法规、规范性文件以及《广东太安堂药业股份有限公司章 程》等有关规定，本人作为广东太安堂药业股份有限公司（以下简称"公司"） 第六届董事会独立董事，我们对 2023 年半年度公司控股股东及其关联方占用公 司资金情况和公司对外担保情况进行了认真了解和查验，发表独立意见如下： 一、关于控股股东及其他关联方占用公司资金情况的独立意见 报告期内，公司存在以前年度控股股东及其关联方非经营性占用资金情况。 截至报告期末，控股股东及其关 ...

股票代码：002433 股票简称：*ST 太安 公告编号：2023-081 经与会监事认真审议，以记名投票表决方式进行表决，通过了如下事项： （一）审议通过《公司2023年半年度报告及摘要》 根据《证券法》和《公司章程》等有关规定，监事会对公司董事会编制的《公 司2023年半年度报告及摘要》进行认真审核，监事会认为：公司2023年半年度报 告编制和审议程序符合法律、法规、中国证监会及深圳证券交易所的规定，报告 内容真实、准确、完整反映了公司的实际情况，不存在任何虚假记载、误导性陈 述或者重大遗漏。 表决结果：3票同意、0票反对、0票弃权。 三、备查文件 广东太安堂药业股份有限公司 第六届监事会第四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 广东太安堂药业股份有限公司（以下简称"公司"）第六届监事会第四次会 议于 2023 年 8 月 29 日在公司麒麟园二楼会议室以现场表决与通讯表决相结合的 方式召开，会议通知已于 2023 年 8 月 28 日以电子邮件、传真、送达、电话等方 式发出。会议应参会监事 3 名，实际参加会议 ...

二、会议审议情况 经与会董事认真审议，以记名投票表决方式进行表决，通过了如下事项： （一）审议通过《公司2023年半年度报告及摘要》 股票代码：002433 股票简称：*ST 太安 公告编号：2023-080 广东太安堂药业股份有限公司 第六届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 广东太安堂药业股份有限公司(以下简称"公司")第六届董事会第五次会议 于2023年8月29日在公司麒麟园二楼会议室以现场表决与通讯表决相结合的方式 召开，会议通知已于2023年8月28日以电子邮件、传真、送达、电话等方式发出。 会议应参会董事8名，实际参加会议董事8名，符合召开董事会会议的法定人数。 本次会议由董事长柯少彬先生主持，公司监事及高级管理人员列席本次会议。本 次会议的召集、召开和表决程序符合《公司法》、《公司章程》及公司《董事会议 事规则》等有关法律、行政法规、部门规章、规范性文件的规定，会议合法有效。 广东太安堂药业股份有限公司董事会 二〇二三年八月三十日 表决结果：8票同意、0票反对、0票弃权。 《广东太安堂药业股 ...

| 大股东及其附 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 属企业 | | | | | | | | | | | 太安堂（亳州）中药饮片有限公司 | 全资子公司 | 其他应收款 | 603,190,010.86 | | 603,190,010.86 | - 往来款 | 非经营性往来 | | | 抚松太安堂长白山人参产业园有限公司 | 全资子公司 | 其他应收款 | 323,991,539.43 | 240,000.00 | | 324,231,539.43 往来款 | 非经营性往来 | | | 抚松麒麟房地产开发有限公司 | 全资子公司 | 其他应收款 | 15,009,999.99 | 120,000.00 | 60,000.00 | 15,069,999.99 往来款 | 非经营性往来 | | | 上海金皮宝制药有限公司 | 全资子公司 | 其他应收款 | | 2,987,026.98 | 1,642,126.98 | 1,344,900.00 往来款 | 非经营性往来 | | | 上海太安堂云健康 ...